Voltar à classificação

Clariant AG (CLZNY)

Valor Justo
Basic MaterialsSpecialty ChemicalsSwitzerland

Fundamental

49

Preço

$10.70

Capitalização de Mercado

$3.55B

Parte 1 · Quanto vale a empresa

Visão Geral

Clariant makes specialty chemicals — ingredients and additives that go into other companies' products rather than finished goods sold directly to consumers. Its formulations end up in shampoos, detergents and cosmetics, in catalysts that refineries and chemical plants use to run reactions more efficiently, and in additives that keep plastics, coatings and other materials stable. Customers are industrial and consumer-goods manufacturers who need a specific chemical property, not a brand name.

Como gera receita

Revenue comes from selling formulated chemicals by volume at prices that reflect both the cost of raw materials — often oil-derived — and the performance the formulation delivers, so pricing power varies a lot by product: a proprietary catalyst commands a different margin than a commodity-like additive. The business runs through three units — Care Chemicals, Catalysts, and Adsorbents & Additives — each selling into different end industries with different demand cycles.

O que impulsiona a procura

Moderadamente cíclico

Care Chemicals sells mostly into personal care and household products, which hold up reasonably well in a downturn, while Catalysts and Adsorbents & Additives depend more on industrial output and energy-sector investment, which is more sensitive to the economic cycle. The mix of the three units softens, but does not eliminate, Clariant's exposure to industrial demand swings.

Os argumentos a favor

Buyers argue that specialty formulations command better margins than commodity chemicals, that the EBITDA margin has improved for three straight years even as reported sales declined, and that a more focused three-unit portfolio after years of divestitures lets management run the business more efficiently.

Os argumentos contra

Sellers fear that flat-to-declining sales in local currency show weak underlying demand that margin gains from cost cutting cannot offset forever, that currency translation can erode reported results even when the underlying business is stable, and that Catalysts and Adsorbents & Additives remain exposed to industrial and energy cycles outside the company's control.

Written by the editors, published on 18 de agosto de 2026

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 18 de setembro de 2026 with claude-haiku-4-5 — shared with all users

BASF SEBFFAF
P/E: 7.5Score: 61Market cap: $46.25B

BASF is the only rival that meets Clariant in all three of its business units at once, selling personal- and home-care ingredients, process catalysts for syngas and petrochemicals, and adsorbents to the same industrial buyers.

Evonik Industries AGEVK

Evonik's Consumer Specialties and Coatings & Additives units sell surfactants and care ingredients to the same cosmetics, detergent and coatings formulators that Clariant's Care Chemicals and Additives businesses supply.

Croda International PlcCRDA

Croda competes head-on with Clariant's Care Chemicals unit in surfactants and speciality ingredients for personal care and crop protection formulations.

LANXESS AGLXS

Lanxess sells flame retardants, lubricant additives and preservatives for home and personal care into the same additive and consumer-protection markets as Clariant's Additives business.

Nouryon (Nouryon Chemicals Holding B.V.)Not tracked

Spun out of AkzoNobel and privately held, Nouryon supplies surfactants and speciality ingredients for cleaning, personal care and agriculture, bidding for the same formulator accounts as Clariant Care Chemicals.

Balanço & Liquidez

Receita

$3.77B

Últimos 12 meses até o último trimestre divulgado — estimativa a partir de métricas por ação

Resultado Líquido

$-31M

Últimos 12 meses até o último trimestre divulgado — estimativa a partir de métricas por ação

Fluxo de Caixa Livre

$214M

Capital Próprio Total

$2.02B

Passivo Total

$2.13B

Rácio de Liquidez

1.77

Cobertura de Juros

-

Dívida/EBITDA

3.77

Resultados Por Ação

Receita & Resultado Líquido

Fluxo de Caixa Livre

Decomposição dos Resultados

Demonstração histórica

Margens ao longo do tempo

A dívida ao longo do tempo

Quanto pesa a dívida

Grelha do crescimento

Crescimento — Receitas

Estimativa de Valor Justo

CíclicaJustamente Valorizada

Valor Justo

$9.86

Preço Atual

$10.70

Margem de Segurança

-8.5%

Intervalo de Valor Justo

$9.26 - $10.47

Dispersão entre os métodos de avaliação utilizados, não um intervalo de confiança calibrado estatisticamente.

Métodos de Estimativa

Preço-alvo dos analistas:$10.41
Fluxo de caixa descontado (DCF):Não aplicável a este tipo de empresa
Multiplicador de lucros (P/E):Dados insuficientes para o calcular
Fórmula de crescimento de Graham:Não aplicável a este tipo de empresa
Valor da capacidade de gerar lucro (EPV):$9.20
P/B justificado:Não aplicável a este tipo de empresa
Desconto de dividendos (Gordon):Não aplicável a este tipo de empresa
P/FFO, fundos de operações:Não aplicável a este tipo de empresa
Lucros de meio de ciclo:Dados insuficientes para o calcular
Multiplicador sobre as receitas:Não aplicável a este tipo de empresa
Consenso dos Analistas:Comprar (13B / 7H / 2S)
Última Surpresa de Resultados:-199.64%

Métricas de Avaliação

Rácio P/E

-

ROE

-0.0%

Rácio P/B

1.74

P/FCF

16.53

Margem Bruta

31.0%

ROIC

7.6%

Radar de Rentabilidade

Criação de Valor (Vantagem Competitiva)

ROIC

7.6%

WACC

6.6%

ROIC − WACC

+1.0 pp

O ROIC supera o custo do capital — a empresa está a criar valor para os acionistas.

Critérios de Análise Fundamental

Aprovado (10)

  • ROIC 7.6%
  • Gross Margin 31.0%
  • P/FCF 16.53
  • P/B Ratio 1.74
  • Debt/Equity ratio
  • Operating Margin 10.7%
  • Positive Free Cash Flow
  • Current Ratio
  • Debt/EBITDA
  • Analyst Consensus 59% Buy

Reprovado (8)

  • Price CAGR -5.32%
  • CapEx intensity
  • DCF valuation (Fairly valued)
  • ROE -1.5%
  • Revenue Growth 5Y 0.3%
  • Earnings Surprise avg -6.6%
  • Net Margin Trend -1.9% vs 5.9%
  • Piotroski F-Score 2/9

Indisponível (9)

  • EPS data insufficient
  • Dividend Payout NaN%
  • Interest Coverage
  • Return on Tangible Assets
  • Low reliance on intangibles
  • Price below Graham Number
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)
  • Share Dilution (missing shares data)

Piotroski F-Score

2/9

Preocupações financeiras graves

score
criteria

Qualidade dos Resultados

-

Baixa qualidade: investigar a contabilidade

Diluição de Ações

-

A recomprar ações. Favorável ao acionista

Participações institucionais

Não há declarações institucionais para esta empresa.

Governação

Equipa Executiva

NomeCargoIdade
Mr. Conrad KeijzerChief Executive Officer57
Mr. Oliver RittgenChief Financial Officer-
Mr. Richard Haldimann Ph.D.Chief Strategy & Technology Officer-
Mr. Andreas SchwarzwaelderHead of Investor Relations-
Dr. Judith BischoffGeneral Counsel & Head of Group Legal Services51
Kai RolkerHead of Group Communications-
Priya ThamanChief Human Resources Officer-
Mr. Joachim KrügerHead of Corporate Sustainability & Regulatory Affairs-
Monica FerreiraRegion Head of Latin America-
Mr. Christian VangPresident of BU Care Chemicals & Americas Region-

Risco de Auditoria

10

Risco do Conselho

1

Risco de Remuneração

5

Risco dos Direitos dos Acionistas

9

Parte 2 · O preço e o momento de entrar

Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.

Latest News

Recent headlines for CLZNY, sourced from Markets Gazette.

No recent news for CLZNY.